Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study

INTRODUCTION: Clobetasol propionate (0.05% standard dose formulation), a topical corticosteroid, leads to systemic side-effects like hypothalamic–pituitary–adrenal (HPA) axis suppression at doses as low as 2 g/day. The aim of this study was to evaluate HPA axis suppression, efficacy, and safety of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidgiddi, Srinivas, Naqvi, Syed Mujtaba Hussain, Shenoy, Manjunath, Balraj, Devang Narayan, Kothari, Jayesh, Gupta, Sandesh, Haq, Rizwan, Mittal, Rajan, Mehta, Suyog, Mane, Amey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484418/
https://www.ncbi.nlm.nih.gov/pubmed/34453262
http://dx.doi.org/10.1007/s13555-021-00591-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484418/
https://www.ncbi.nlm.nih.gov/pubmed/34453262
http://dx.doi.org/10.1007/s13555-021-00591-z

Ejemplares similares